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TIIVISTELMÄ
Rytmihäiriölääke digoksiinilla on raportoitu olevan apoptoosia lisäävää ja sytotoksista vaikutusta 
eturauhassyöpäsoluihin. Selvitimme rytmihäiriölääkkeiden käytön ja eturauhassyöpäriskin yhteyttä 
väestöpohjaisessa tapaus-verrokkitutkimuksessamme. Aineisto sisälsi kaikki uudet todetut 
eturauhassyöpätapaukset Suomessa vuosina 1995-2002 Suomen Syöpärekisteristä ja kullekin 
tapaukselle kaltaistetun verrokin Väestörekisterikeskuksesta (24657 tapaus-verrokkiparia). Tiedot 
rytmihäiriölääkeostoista haettiin kansallisesta reseptitietokannasta. 
Aineiston analysoinnissa  käytettiin monivakioitua ehdollista logistista regressiomallia.  Emme 
löytäneet tilastollisesti merkitsevää yhteyttä digoksiinin käytöllä ja yleisen (OR 0.95, 95% CI 0.89-
1.01) tai levinneen (OR 0.90, 95% CI 0.77-1.05) eturauhassyövän riskillä verrattuna ei-käyttäjiin. 
Tulokset olivat samanlaiset kaikille rytmihäiriölääkkeille lukuunottamatta sotalolia, jonka käyttäjillä 
oli alhaisempi levinneen eturauhassyövän riski (OR 0.73, 95% CI 0.56-0.96). Myös yleinen 
eturauhassyövän riski laski sotalolin käyttöajan funktiona. 
Tutkimuksemme osoittaa, että digoksiinin tai muiden tavallisten rytmihäiriölääkkeiden käyttö ei 
yleisesti ole yhteydessä eturauhassyöpäriskiin väestötasolla maksimissaan kahdeksan vuoden 
seurannalla. Kuitenkaan emme voi sulkea pois digoksiinin pitkäaikaisempa suojavaikutusta. 
Kaliumkanavan estäjä sotalolin mahdollinen suojavaikutus vaatii vielä lisätutkimusta.
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Novelty and impact of the work:
This is the first study to comprehensively evaluate the association between antiarrhythmic drug use 
and prostate cancer risk. We could not confirm previously reported decreased prostate cancer risk 
among digoxin users, but found lower risk of advanced prostate cancer among men using beta-
blocker/K+-channel inhibitor sotalol. These findings lessen the enthusiasm to study digoxin as 
prostate cancer preventive agent, but the effects of sotalol warrant further study.
ABSTRACT
Antiarrhythmic drug digoxin has been reported to have apoptosis-inducing and cytotoxic effects on 
prostate cancer cells. We evaluated the association between antiarrhythmic drug use and prostate 
cancer risk in a population-based case-control study. The study included all new prostate cancer 
cases diagnosed in Finland during 1995-2002 and matched controls (24,657 case-control pairs) 
obtained from the Finnish Cancer Registry and the Population Register Center, respectively. 
Information on antiarrhythmic drug purchases was obtained from national prescription database.
Multivariable-adjusted conditional logistic regression model was used for data analysis. Compared 
to never-users of antiarrhythmic drugs, we found no significant association between digoxin use and 
prostate cancer risk overall (OR 0.95, 95% CI 0.89-1.01) or for advanced prostate cancer risk (OR 
0.90, 95% CI 0.77-1.05). The result was similar also for other antiarrhythmic drugs, with the 
exception of sotalol, users of which had decreased risk of advanced prostate cancer (OR 0.73, 95% 
CI 0.56-0.96). Also the overall prostate cancer risk decreased by duration of sotalol use (p for trend 
0.038).  
We show that digoxin or other common antiarrhythmic drugs generally do not associate with 
prostate cancer risk at population level during maximum follow-up of eight years.  However, we 
cannot rule out longer-term protective effects of digoxin. Possible prostate cancer preventive effects 
of K+-channel blocker sotalol deserve further study.
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1 INTRODUCTION
Prostate cancer is the most common malignancy among men in most countries.1 Despite being a 
major public health problem, its etiology is still not well-known. A deeper knowledge of the risk 
factors is needed for prevention and better treatment of the condition.
Digoxin, a commonly used antiarrhythmic agent, inhibits prostate cancer cell growth by increasing 
apoptosis.2,3 The mechanism of action for cardiac glycosides such as digoxin involves inhibition of 
the plasma membrane Na+/K+-ATPase, leading to changes in intracellular K+- and Ca2+- 
concentrations. The apoptosis-inducing effect of digoxin has been proposed to be caused by 
increased Ca2+-uptake in prostate cancer cells,2,3 leading to changes in activity of cyclin-dependent 
kinase Cdk5, p35 cleavage and p25 formation.4 Cardiac glycosides also decrease prostate specific 
antigen (PSA) secretion in prostate cancer cells.5 In a mouse model digoxin treatment caused 
decreased blood vessel density and inhibition of HIF-1α expression in castration-resistant xenograft 
tumors, but no reduction in tumor volume.6
On the other hand, digoxin possesses estrogen-mimicking effects, and its use is associated with an 
increased incidence of breast and uterine cancer.7 This would provide another plausible mechanism 
for prostate cancer inhibiting effects. 
Recently, a novel two-stage study both confirmed the cytotoxic effects of digoxin against prostate 
cancer cells, and also reported decreased prostate cancer incidence among men who had used 
digoxin regularly for over ten years within a cohort of 47,884 men.8
We evaluated whether the use of digoxin or, for comparison, other antiarrhythmic agents is related 
to overall or advanced prostate cancer risk at population level.
2 MATERIALS AND METHODS
2.1 study population
We used a nationwide case-control study population including all newly diagnosed prostate cancer 
cases in Finland during 1995-2002. The study population has been extensively described 
previously.9-12 
In brief, all new prostate cancer cases in Finland between 1995 and 2002 (25,029 men) were 
obtained from the Finnish Cancer Registry. The nationwide registry covers over 99% of all prostate 
cancer patients in Finland.13 The registry data includes information on primary site of cancer, 
histology, date, and method of diagnosis. Tumor stage was available for 13,616 cases (55% of all 
cases). Of these, 73% were localized. The registry had no information on Gleason score or PSA 
values or screening activity prior to the diagnosis. 
Practically all the cases were histologically confirmed (99.3%). In a small portion the diagnosis was 
based on clinical (0.4%), radiological (0.3%), other specific laboratory findings (0.02%). 185 cases 
were excluded for unknown method of diagnosis (0.7%). In addition, 66 duplicate cases were 
excluded.
For each case, the Population Registry Center of Finland randomly selected a control from among 
the men who were of the same age (±1 year), living in the same area and were free of prostate 
cancer at the time of the cases’ diagnosis. We used incidence density sampling for control selection, 
and thus 963 men were considered twice in the analysis; first as a control and then as a case in 
another case-control pair after being diagnosed with prostate cancer at a later time. Matched 
controls could not be found for 121 cases in the oldest age group. In the end, a total of 24,657 
individually matched case-control pairs were included in the analysis.
The study was approved by the ethics committee of the Pirkanmaa health care district, Finland 
(ETL R03290).
2.2 information on medication use
Information on reimbursed physician-prescribed medication purchases during 1995–2002 was 
obtained from the comprehensive nationwide prescription database of the Social Insurance 
Institution (SII) of Finland. The SII is a governmental agency financed through tax revenues, 
providing reimbursements for the cost of medicines prescribed by a physician with the exception of 
hospital inpatients.14 The reimbursement is available for all Finnish residents, for each purchase of a 
SII approved reimbursable drug and covers 50-100% of the costs depending on the severity of the 
disease.
We included all antiarrhythmic agents being used within our study population during 1995-2002. 
Beta-blockers, which are used both as antihypertensive and as antiarrhythmic drugs, have been 
analyzed in an earlier study along with antihypertensive medication.10 The only beta-blocker 
included in this analysis was sotalol, which is mainly used as an antiarrhythmic agent.
The drugs included in this analysis were amiodarone, digoxin, disopyramide, etilefrine, flecainide, 
quinidine, mexiletine, propafenone, sotalol and tocainide. Of these, quinidine, disopyramide, mexiletine, 
tocainide, propafenone and flecainide function as Na+-channel inhibitors. Amiodarone and sotalol 
are K+-channel inhibitors. Amiodarone also has beta-blocker function. Etilefrine is a 
sympathomimetic agent that is suggested to stimulate both alpha- and beta-receptors. Digoxin's 
mechanism of action is not completely understood, but it involves an effect on Na+/K+ ATPase 
pump.
2.3 statistical analysis
Medication use was followed from January 1st, 1995 up to the month of diagnosis of the prostate 
cancer cases. For the controls, medication use was followed until the date of diagnosis of the 
corresponding matched case, ensuring equal available exposure time for the cases and the controls.
The amount of antiarrhythmic medication use was standardized across the drug groups by dividing 
the purchased mg amount of a drug with a quantity corresponding one Defined Daily Dose (DDD) 
recommended by the WHO.15 Total number of DDDs for each individual drug was combined for a 
total sum of DDDs of all antiarrhythmic drugs used by each person.
Propensity for antiarrhythmic drug usage as function of age and usage of other types of drugs was 
estimated using a logistic regression method with antiarrhythmic drug usage as the dependent 
variable and age, use of 5α-reductase inhibitors, alpha-blockers, anti-diabetic drugs, cholesterol-
lowering drugs and antihypertensive drugs as independent variables. The propensity score for each 
was added together for total propensity score. The analysis was repeated by quartiles of the total 
propensity score to estimate the drugs effect within subpopulations that are comparable in their 
likelihood to use antiarrhythmic drugs.
Non-users of antiarrhythmic drugs were the reference group in all analyses. We used conditional 
logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for overall 
prostate cancer risk and risk of advanced prostate cancer among the medication users. The analysis 
was adjusted for age alone (age-adjusted model) or additionally for use of above mentioned drug 
groups (multivariable-adjusted model).
Each drug was analyzed separately and in combination with other antiarrhythmic drugs. We 
compared prostate cancer risk by ever-use of the drugs, and also in analysis stratified in quartiles of 
the amount and duration of medication use.  We analyzed trends in prostate cancer risk by 
cumulative medication use by adding total DDDs or years of usage into the logistic regression 
model as a continuous variable.
In sensitivity analyses we aimed to estimate the effect of previous PSA-testing by stratifying the 
analysis by simultaneous usage of drugs used in management of benign prostatic hyperplasia 
(BPH); 5α-reductase inhibitors and alpha-blockers.
The data was analyzed using Stata 8.2 software (College Station, Texas).
3 RESULTS
3.1 population characteristics
Overall, the prevalence of digoxin use was similar between the cases and controls; 10.6% for the 
cases (2,616 men) and 10.3% for the controls (2,550 men) (Table 1). The overall prevalence of 
antiarrhythmic drug use was 13.6%, with no difference between cases and controls. Of the other 
drug groups, prevalence of use for non-steroidal anti-inflammatory drugs (NSAIDs), BPH 
medication, cholesterol-lowering medication and antihypertensive drugs was higher among the 
cases, whereas the prevalence of antidiabetic medication use was lower (Table 1). 
3.2 digoxin use and prostate cancer
Digoxin use was not significantly associated with overall prostate cancer risk either in the age-
adjusted analysis (OR 1.03, 95% CI 0.97-1.09) or the multivariable-adjusted analysis (OR 0.96, 
95% CI 0.90-1.02). (Table 2).
The risk of advanced prostate cancer in digoxin users was lower than the overall prostate cancer risk 
(multivariable-adjusted OR 0.89, 95% CI 0.76-1.05), but the difference compared to the non-users 
remained non-significant (Table 2).
There was no association between digoxin use and prostate cancer risk, either overall or advanced, 
within any quartile of digoxin usage (Table 3). The multivariable-adjusted trend analysis in prostate 
cancer risk by cumulative amount or duration of digoxin use likewise showed no associations with 
overall or advanced prostate cancer.
3.3 other antiarrhythmic drugs and prostate cancer
Usage of any antiarrhythmic drug use was not associated with the risk of either overall (OR 0.96, 
95% CI 0.91-1.01) or advanced prostate cancer risk (OR 0.90, 95% CI 0.77-1.04) (Table 2). The 
difference between users and non-users of antiarrhythmic drugs remained non-significant in each 
quartile of total DDD amount of use, although there was a borderline significant decreasing trend in 
overall prostate cancer risk by duration of usage (p for trend = 0.058) (Table 3).
When analyzed separately, use of Na+-channel blockers was not associated with prostate cancer risk 
(Table 2). No individual Na+-channel blocker had an effect on overall or advanced prostate cancer 
risk, either. The amount or duration of Na+-channel blockers use did not affect the risk in the 
analysis stratified by quartiles (Table 3) nor in the trend analysis.
The K+-channel blockers amiodarone and sotalol as a group were not associated with either overall 
or advanced prostate cancer risk; multivariable-adjusted OR 0.94, 95% CI 0.85-1.03 and OR 0.78, 
95% CI 0.60-1.02, respectively (Table 2). However, use of sotalol was associated with a decreased 
risk of advanced prostate cancer; OR 0.73, 95% CI 0.56-0.96 (Table 2). Also overall prostate cancer 
risk was lower among men who had used sotalol for five years or longer; OR 0.68, 95% CI 0.55-
0.85 (Table 3). The association with advanced prostate cancer risk was not dose-dependent, but we 
observed an inverse association between overall prostate cancer risk and years of sotalol usage (p 
for trend = 0.038) (Table 3).
3.4 sensitivity analyses
A sensitivity analysis stratified by quartiles of propensity score confirmed the lack of association 
between prostate cancer and use of digoxin or other antiarrhythmic drugs, confirming that the 
association is not modified by the likelihood of being a user of this drug group (Table 4). The risk 
estimates of advanced prostate cancer among sotalol users were uniformly lowered, but statistically 
non-significant.
An analysis stratified by simultaneous use of BPH drugs (5α-reductase inhibitors and/or alpha-
blockers) shower no clear effect modification, either (Table 5). The risk of advanced prostate cancer 
was decreased among sotalol users regardless of BPH-medication usage (OR 0.70, 95% CI 0.50-
0.96 and OR 0.21, 95% CI 0.04-1.24 among users and non-users of BPH medication, respectively) 
(Table 5).
When we limited the analysis to include only cases diagnosed during 2000-2002, both digoxin use 
and antiarrhythmic drug use in general were associated with slight reduction in overall prostate 
cancer risk (OR 0.89, 95% CI 0.80-0.98 and OR 0.91, 95% CI 0.84-0.99, respectively), but no trend 
by the cumulative dose of medication use was observed for either.  The risk of advanced prostate 
cancer among digoxin, sotalol and any antiarrhythmic drug users did not differ significantly from 
the non-users in this sensitivity analysis. 
4 DISCUSSION
Our results suggest that use of digoxin or other antiarrhythmic agents in general does not affect 
prostate cancer risk at population level with maximum exposure time of eight years. However, 
sotalol use was inversely associated both with advanced prostate cancer risk, and long-term users 
also had lower risk of overall prostate cancer. This drug deserves further study as prostate cancer 
preventive agent.
A previous study has reported promising results of digoxin's inhibitory effects on prostate cancer 
cell lines and also that regular long-term use of digoxin is related to a lower prostate cancer risk in 
the Health Professional´s Follow-up Study.8 In the present study we found no evidence of lower 
overall or advanced prostate cancer risk among digoxin users at population-level. Furthermore, we 
found no dose-response in the risk by the cumulative amount or duration of digoxin use. The 
difference between our results and the earlier study is likely explained with our exposure time being 
eight years at maximum. In the Health Professional´s Follow-up Study the decreased prostate 
cancer risk among digoxin users was driven by the very long-term users, i.e. when the analysis was 
stratified by duration of digoxin use the risk decrease was observed only in men who had used the 
drug for 10 years or longer.8 In concordance to our results, digoxin use for less than 10 years was 
not associated with prostate cancer risk in Health Professional’s Follow-up Study, either.8 This 
strongly suggests that digoxin’s protective effects against prostate cancer likely require a 
considerably long induction period when the drug is being used at the clinical dose range. This 
lessens the enthusiasm to study digoxin’s prostate cancer preventive effects in clinical trials.
The relationship between use of other antiarrhythmic drugs and prostate cancer has not been studied 
earlier. Overall, use of any antiarrhythmic drug was not associated with the risk of overall or 
advanced prostate cancer. An exception was sotalol, which has both K+-channel inhibitor and beta-
blocker activity. Sotalol users had decreased risk of advanced prostate cancer, and also lowered 
overall prostate cancer risk in long-term users. This is a novel finding. Further, inverse association 
with advanced prostate cancer persisted in all sensitivity analyses, suggesting that sotalol may 
indeed prove to be an interesting prostate cancer preventive agent.
In our previous study on antihypertensive drugs and prostate cancer risk within this same study 
population we observed a slightly increased overall prostate cancer risk, but no change in risk of 
advanced disease among beta-blocker users.10 Thus it is probably not sotalol’s beta-blocking 
properties that affect prostate cancer risk. We analyzed sotalol together with antiarrhythmic drugs 
because this is the most common indication of use for this drug. The difference between sotalol and 
other beta-blockers is sotalol's function as a potassium-channel inhibitor in addition to its beta-
blocker function. Potassium-channel activity and expression have been suggested to affect prostate 
carcinogenesis,16 possibly by altering intracellular Ca2+ concentrations.17 Interestingly, also 
digoxin’s antitumor effects have been suggested to be mediated by changes in intracellular Ca2+.2,3 
Control of intracellular Ca2+ as a way to limit prostate cancer cell growth merits further study. 
However, the association between sotalol and advanced prostate cancer risk was not dose-
dependent, and use of the other potassium-channel blocker, amiodarone, was not associated with 
prostate cancer risk in our study. Thus further study is required to affirm our findings.
Our study has important strengths. We had a large population-based study population representing 
the entire Finland. This allowed enough statistical power to analyze the impact of rarely used drugs, 
such as digoxin on prostate cancer incidence, and even on advanced prostate cancer. Our 
information on medication usage was obtained from a comprehensive nationwide prescription 
database which records information on drug purchases independent of disease status. The controls 
in our population were individually matched to the cases for age and residence area at the time of 
diagnosis to avoid confounding by these attributes. The population in Finland is racially 
homogenous consisting of 98% Caucasians. Thus race is unlikely to be a confounding factor in our 
study.
Our study also has weaknesses that should be considered. We had no information on the 
antiarrhythmic drug use prior to 1995 which may lead to underestimation of cumulative duration 
and amount of medication use for those persons who had a long history of antiarrhythmic drug use 
prior to 1995. This would presumably bias our results towards the null. Indeed, when we evaluated 
this bias in a sensitivity analysis limited to include only the cases diagnosed during 2000-2002, i.e. 
using the case-control pairs with longest information on medication use before the diagnosis, we 
found slightly decreased overall prostate cancer risk among digoxin users. This further supports the 
notion that very long-term digoxin use might have a prostate cancer risk decreasing effect.
We did not have information on PSA testing activity within our study population, which could have 
been more common among antiarrhythmic drug users than non-users, possibly creating a detection 
bias that elevates the observed prostate cancer risk in medication users and masks possible 
protective associations. We evaluated this bias by stratifying our analysis by BPH medication usage. 
Diagnostic work-up of BPH involves PSA testing for exclusion of prostate cancer. Thus BPH 
medication users present a group of PSA tested men. However, the association between 
antiarrhythmic drug use and prostate cancer risk was not modified by BPH medication usage, thus 
this detection bias is unlikely to affect our results to any great degree. 
Tumor stage was known for slightly more than half of the cases (55%). The proportion of cases 
with missing information on stage was higher among antiarrhythmic drug users and digoxin users 
(48.7% and 48.5%, respectively) than among non-users of antiarrhythmic drugs (44.6%). This could 
have masked possible protective associations for advanced prostate cancer among users of digoxin 
or other antiarrhythmic drugs.
Finally, we did not have information on lifestyle factors apart from medication use, such as BMI, 
smoking or diet. These could have caused confounding in either direction depending on their 
association with antiarrhythmic medication usage.
We have shown that use of antiarrhythmic drugs in general does not associate with prostate cancer 
risk. Further, our study confirms that digoxin does not have a population-level prostate cancer 
preventive effect during a maximum exposure period of eight years. However, we cannot rule out 
longer-term protective effects of digoxin that have been suggested by previous research. Studies 
with longer follow-up time will be needed. The K+-channel inhibitor/beta-blocker sotalol showed 
promise for a protective effect against advanced prostate cancer. If this is confirmed in further 
studies, sotalol may prove to be a promising prostate cancer preventive agent.
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